The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What factors should be considered when sequencing therapy in R/R follicular lymphoma?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, about what factors should be considered when sequencing therapy in relapsed/refractory (R/R) follicular lymphoma.

What factors should be considered when sequencing therapy in R/R follicular lymphoma?

Salles highlights the different elements to consider when sequencing therapy in R/R follicular lymphoma, which includes realizing new biopsies to rule out histological transformations, evaluating the treatment options, and considering the toxicities accompanying different therapies.

Share: